Loading...
Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)
INTRODUCTION: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimum...
Na minha lista:
| Udgivet i: | BMJ Open Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5783109/ https://ncbi.nlm.nih.gov/pubmed/29379609 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2017-000174 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|